Terms: = Bone cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA
297 results:
1. Characterizing the presentation, management, and clinical outcomes of patients with intradural spinal chordomas: a systematic review.
Saint-Germain MA; Kramer P; Weber-Levine C; Jiang K; Al-Mistarehi AH; Redmond KJ; Lee SH; Bettegowda C; Theodore N; Lubelski D
Neurosurg Focus; 2024 May; 56(5):E14. PubMed ID: 38691865
[TBL] [Abstract] [Full Text] [Related]
2. Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity.
Shi P; Lin Z; Song Y; Li Z; Zeng M; Luo L; Cao Y; Zhu X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):159. PubMed ID: 38530432
[TBL] [Abstract] [Full Text] [Related]
3. High expression of BCat1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
[TBL] [Abstract] [Full Text] [Related]
4. Somatic Versus Germline: A Case Series of Three Children With
Tam LT; Cole B; Stasi SM; Paulson VA; Wright JN; Hoeppner C; Holtzclaw S; Crotty EE; Ellenbogen RG; Lee A; Ermoian RP; Lockwood CM; Leary SES; Ronsley R
JCO Precis Oncol; 2024 Jan; 8():e2300333. PubMed ID: 38207225
[TBL] [Abstract] [Full Text] [Related]
5. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
[TBL] [Abstract] [Full Text] [Related]
6. Adamantinoma of the Ulnar Shaft Reconstructed With a Vascularized Free Fibula.
Schutz JF; Iorio ML; Marshall CB; Clay MR; Gimarc DC; Park A
Orthopedics; 2024; 47(2):e102-e105. PubMed ID: 37921530
[TBL] [Abstract] [Full Text] [Related]
7. Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.
Němčíková P; Brunerová L
Vnitr Lek; 2023; 69(5):312-315. PubMed ID: 37827829
[TBL] [Abstract] [Full Text] [Related]
8. Prophylactic platelet transfusion response in critically ill patients: a prospective multicentre observational study.
Reizine F; Le Marec S; Le Meur A; Consigny M; Berteau F; Bodenes L; Geslain M; McQuilten Z; Le Niger C; Huntzinger J; Seguin P; Thibert JB; Simon D; Reignier J; Egreteau PY; Tadié JM; Huet O; Asfar P; Ehrmann S; Aubron C
Crit Care; 2023 Sep; 27(1):373. PubMed ID: 37759268
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic capability of 18F-PSMA PET-MRI and pelvic MRI plus bone scan in treatment-naive prostate cancer: a single-center paired validating confirmatory study.
Qiao Z; Wang S; Wang H; He B; Shi Z; Zhou H; Yang Q; Chen X; You Z; Zhao J; Wang H
Int J Surg; 2024 Jan; 110(1):87-94. PubMed ID: 37738021
[TBL] [Abstract] [Full Text] [Related]
10. Pediatric head and neck manifestations associated with multiple endocrine neoplasia syndromes.
Jellins T; Hill M; Prager JD; Francom CR; Chan CM; Schneider KW; Sharma A; Herrmann BW
Int J Pediatr Otorhinolaryngol; 2023 Oct; 173():111703. PubMed ID: 37604101
[TBL] [Abstract] [Full Text] [Related]
11. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast cancer Patients: Study Protocol of a Randomized Controlled Trial.
Zou X; Chen ZY; Yang YH; Qiao Y; He SJ; Li Q; Chen WL; Zhang XY; Li SY; Sha SY; Hu MH; Zhang XY; Yang MJ; Wang RP; Wu HG; Shi Y; Xue XH; Ji YJ
Integr Cancer Ther; 2023; 22():15347354231188679. PubMed ID: 37565358
[TBL] [Abstract] [Full Text] [Related]
12. Prostate cancer: Under-representation of African American Men in Research Studies Used in the Latest NCCN Guidelines.
Lubarsky R; Ambinder D; Barnett J; Choudhury M; Saji A; Fishman AI; Fullerton S; Phillips JL
Urology; 2023 Oct; 180():28-34. PubMed ID: 37479145
[TBL] [Abstract] [Full Text] [Related]
13. Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome.
Guijarro F; López-Guerra M; Morata J; Bataller A; Paz S; Cornet-Masana JM; Banús-Mulet A; Cuesta-Casanovas L; Carbó JM; Castaño-Díez S; Jiménez-Vicente C; Cortés-Bullich A; Triguero A; Martínez-Roca A; Esteban D; Gómez-Hernando M; Álamo Moreno JR; López-Oreja I; Garrote M; Risueño RM; Tonda R; Gut I; Colomer D; Díaz-Beya M; Esteve J
Blood Adv; 2023 Oct; 7(19):5799-5811. PubMed ID: 37450374
[TBL] [Abstract] [Full Text] [Related]
14. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract] [Full Text] [Related]
15. Expression variations of DNA damage response genes atm and ATR in blood cancer patients.
Parvez A; Mahjabeen I; Mehmood A; Khan AU; Nisar A; Kayani MA
Mol Genet Genomics; 2023 Sep; 298(5):1173-1183. PubMed ID: 37338595
[TBL] [Abstract] [Full Text] [Related]
16. The FBXO32/ATR/atm axis acts as a molecular switch to control the sensitivity of osteosarcoma cells to irradiation through its regulation of EXO1 expression.
Lu Y; Huang P; Li Y; Liu W; Li J; Zhao R; Feng H; Shi C; Cao G
Acta Biochim Biophys Sin (Shanghai); 2023 May; 55(5):842-852. PubMed ID: 37227155
[TBL] [Abstract] [Full Text] [Related]
17. Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD.
Thompson PA; Keating MJ; Ferrajoli A; Jain N; Peterson CB; Garg N; Wang SA; Jorgensen JL; Kadia TM; Bose P; Pemmaraju N; Short NJ; Wierda WG
Leukemia; 2023 Jul; 37(7):1444-1453. PubMed ID: 37138019
[TBL] [Abstract] [Full Text] [Related]
18. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Abou Dalle I; Labopin M; Kröger N; Schroeder T; Finke J; Stelljes M; Neubauer A; Blaise D; Yakoub-Agha I; Salmenniemi U; Forcade E; Itäla-Remes M; Dreger P; Bug G; Passweg J; Heuser M; Choi G; Brissot E; Giebel S; Nagler A; Ciceri F; Bazarbachi A; Mohty M
Bone Marrow Transplant; 2023 Jul; 58(7):784-790. PubMed ID: 37041215
[TBL] [Abstract] [Full Text] [Related]
19. Frailty and sarcopenia within the earliest national Dutch childhood cancer survivor cohort (DCCSS-LateR): a cross-sectional study.
van Atteveld JE; de Winter DTC; Pluimakers VG; Fiocco M; Nievelstein RAJ; Hobbelink MGG; Kremer LCM; Grootenhuis MA; Maurice-Stam H; Tissing WJE; de Vries ACH; Loonen JJ; van Dulmen-den Broeder E; van der Pal HJH; Pluijm SMF; van der Heiden-van der Loo M; Versluijs AB; Louwerens M; Bresters D; van Santen HM; Hoefer I; van den Berg SAA; den Hartogh J; Hoeijmakers JHJ; Neggers SJCMM; van den Heuvel-Eibrink MM;
Lancet Healthy Longev; 2023 Apr; 4(4):e155-e165. PubMed ID: 37003274
[TBL] [Abstract] [Full Text] [Related]
20. Teloxantron inhibits the processivity of telomerase with preferential DNA damage on telomeres.
Maciejewska N; Olszewski M; Jurasz J; Baginski M; Stasevych M; Zvarych V; Folini M; Zaffaroni N
Cell Death Dis; 2022 Nov; 13(11):1005. PubMed ID: 36437244
[TBL] [Abstract] [Full Text] [Related]
[Next]
